Fulcrum Therapeutics, Inc. filed an 8-K on December 10, 2025, announcing a public offering of 11,851,853 shares of common stock at $13.50 per share and pre-funded warrants for 1,111,193 shares, potentially raising net proceeds of approximately $164.1 million, and up to $188.1 million if underwriters exercise their option for additional shares.